BioCentury
ARTICLE | Company News

Two approvals for big pharma

April 24, 2000 7:00 AM UTC

Aventis (AVE) and Novartis (East Hanover, N.J.) each received marketing approval from the FDA. AVE obtained approval for its Lantus insulin glargine (rDNA origin) injection. Lantus is indicated for once-daily subcutaneous administration at bedtime to treat adults with Type II diabetes requiring long-acting insulin to control hyperglycemia and to treat adults and children with Type I diabetes. The NDA was submitted in the U.S. and Europe in April 1999. AVE plans to make the product available later this year. ...